{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-24-000015","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.089120+00:00","generated_at":"2026-05-31T10:40:02.708189+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PTC Therapeutics Q2 revenue $187M; net loss narrows to $99M; NDAs submitted","bullets":["Q2 total revenue $186.7M vs $213.8M YoY; DMD franchise $118M (Translarna $70M, Emflaza $47M).","Net loss $99.2M improved from $198.9M loss; cash $1.09B after $250M Royalty Pharma put option.","Submitted NDA for sepiapterin (PKU) and resubmitted NDA for Translarna (nmDMD) to FDA in July 2024.","Full-year 2024 revenue guidance $700M-$750M; GAAP R&D+SG&A $740M-$835M.","BLA for AADC deficiency gene therapy accepted with priority review; PDUFA date Nov 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-24-000015","json":"https://secwatch.observer/filing/0001070081-24-000015.json","markdown":"https://secwatch.observer/filing/0001070081-24-000015.md","text":"https://secwatch.observer/filing/0001070081-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/0001070081-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/tmb-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:40:02.708189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}